Quantcast

Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media

April 13, 2009

BOTHELL, Wash., April 13 /PRNewswire-FirstCall/ — BioLife Solutions, Inc.
(OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary
cGMP hypothermic storage and cryopreservation media products for cells,
tissues, and organs, today announced that the Rutgers University Cell and DNA
Repository (RUCDR), the world’s largest university-based biologics repository,
has adopted the Company’s CryoStor as the exclusive cryopreservation media for
its transformed lymphocyte cell lines (LCL), which are used throughout the
world by researchers working to find genetic causes of common, complex
diseases such as alcohol/addiction, diabetes, autism, and numerous mental
disorders.

Douglas A. Fugman, Ph.D., Managing Director of RUCDR, explained the
decision to transition from an in-house formulated media containing culture
media and fetal bovine serum to CryoStor by stating, “We continually strive to
optimize our cell processing protocols to improve the quality of the cell
lines we make available to researchers around the world. Our technical
evaluation clearly indicated that CryoStor offered advantages in post-
preservation cell recovery and we view pre-formulated, serum and protein free
CryoStor as the best-in-class biopreservation media for cell banking
applications.”

Mike Rice, BioLife’s chairman and CEO, noted, “We view this product
adoption by RUCDR as further validation that our initiative to raise the
quality and regulatory bar for biopreservation media products is being
recognized and valued in our strategic markets. Dr. Fugman’s operations team
processes over 36,000 cell lines annually and this represents significant
volume demand for CryoStor. We expect to begin fulfilling orders in a custom
package to support RUCDR within 60 days, following final validation of our
internal manufacturing facility in Bothell.”

About BioLife Solutions, Inc:

BioLife Solutions develops and markets patented hypothermic
storage/transport and cryopreservation media products for cells, tissues, and
organs. The Company’s proprietary HypoThermosol(R) and CryoStor(TM) platform
of biopreservation media products are marketed to academic research
institutions, hospitals, and commercial companies involved in cell therapy,
tissue engineering, cord blood banking, drug discovery, and toxicology
testing. BioLife’s cGMP products are serum-free and protein-free, fully
defined, and formulated to reduce preservation-induced, delayed-onset cell
damage and death. BioLife’s enabling technology provides research and
clinical organizations significant improvement in post-preservation cell and
tissue viability and function. For more information please visit
http://www.biolifesolutions.com.

About RUCDR:

Rutgers University Cell and DNA Repository (RUCDR) is led by Scientific
Director Jay A. Tischfield, Ph.D., FFACMG, and plays a key role in research
aimed at understanding the genetic causes of common, complex diseases. RUCDR
activities will enable gene discovery leading to diagnoses, treatments and,
eventually, cures for these diseases. RUCDR assists researchers throughout the
world by providing the highest quality biomaterials, technical consultation,
and logistical support. RUCDR is the largest university based repository in
the world, located on the Busch Campus of Rutgers University, Piscataway, New
Jersey
. For more information, please visit http://www.rucdr.org.

This news release contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include any statements that relate to the intent,
belief, plans or expectations of the Company or its management, or that are
not a statement of historical fact. Any forward-looking statements in this
news release are based on current expectations and beliefs and are subject to
numerous risks and uncertainties that could cause actual results to differ
materially. Some of the specific factors that could cause BioLife Solutions’
actual results to differ materially are discussed in the Company’s recent
filings with the Securities and Exchange Commission. BioLife Solutions
disclaims any obligation to update any forward-looking statements as a result
of developments occurring after the date of this press release.

     Media Relations:            Investor Relations:
     Len Hall                    Matt Clawson
     Allen & Caron Inc.          Allen & Caron Inc.
     (949) 474-4300              (949) 474-4300
     len@allencaron.com          matt@allencaron.com

SOURCE BioLife Solutions, Inc.


Source: newswire



comments powered by Disqus